Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology

Fode, Mikkel; Salonia, Andrea; Minhas, Suks; Burnett, Arthur L.; Shindel, A.W.

doi:10.1016/j.euf.2019.02.021

Cited by 28 publications

(30 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Late-onset hypogonadism or testosterone deficiency may result in significant detriment to quality of life, and adversely affect the function of multiple organ systems [4]. In a systematic review and metaanalysis, consisting of the 21 studies, Araujo et al [6] demonstrated that difference in the means of the top and bottom third of the standard normal distribution in total testosterone was associated with 35 and 25% increased risk of all-cause and cardiovascular disease mortality, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Testosterone is the principal male sex hormone, and decreases on average by 0.8-2% per year after the age of 40 years. The prevalence of male hypogonadism has been ranged from 2.1 to 9.5% in men aged 40-70 years [4][5][6]. Its rate significantly increases, ranging 10-80% in several morbid diseases [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

“…The prevalence of male hypogonadism has been ranged from 2.1 to 9.5% in men aged 40-70 years [4][5][6]. Its rate significantly increases, ranging 10-80% in several morbid diseases [4][5][6]. Male late-onset hypogonadism has been reported as a risk factor for diabetes, chronic obstructive pulmonary disease, metabolic syndrome, dyslipidemia, thrombotic and cardiovascular disease, leading to increased mortality in the general population [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study

et al. 2020

View full text Add to dashboard Cite

Objective: To investigate effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected male patients. Methods: This prospective cohort study included 221 consecutive male patients (>18 years old) with laboratory confirmed SARS-CoV-2 who had been hospitalized due to COVID-19. The patients were divided into 3 groups: Asymptomatic patients (n: 46), symptomatic patients who were hospitalized in the internal medicine unit (IMU) (n: 129), and patients who were hospitalized in the intensive care unit (ICU) (n: 46). Results: As serum total testosterone level at baseline decreases, probability (%) to be in the ICU significantly increases (p ¼ 0.001). As serum total testosterone level at baseline decreases, probability (%) of mortality significantly increases (p ¼ 0.002). In the patients who had pre-COVID-19 serum gonadal hormones test (n: 24), serum total testosterone level significantly decreased from pre-COVID-19 level of 458 ± 198 ng/dl to 315 ± 120 ng/dl at the time of COVID-19 in the patients (p ¼ 0.003). Conclusions: COVID-19 might deteriorate serum testosterone level in SARS-CoV-2 infected male patients. Low serum total testosterone level at baseline has a significant increased risk for the ICU and mortality in patients with COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Late-onset hypogonadism (LOH) is associated with advancing age and is characterised by symptoms of androgen deficiency and low serum testosterone 1. Hypogonadism with clinical symptoms can lead to decline in exercise tolerance and muscle mass and an attenuation of bone strength, which may significantly reduce quality of life 2.…”

Section: Introductionmentioning

confidence: 99%

Lipid accumulation product and late-onset hypogonadism in middle-aged and elderly men: results from a cross-sectional study in China

et al. 2020

View full text Add to dashboard Cite

ObjectivesHypogonadism in men is related to the deterioration of general health. However, the association between lipid overaccumulation and ageing-related hypogonadism remains an undetermined concept. We aimed to provide an insight into the possible links between the lipid accumulation product (LAP) and late-onset hypogonadism (LOH).SettingSun Yat-sen Memorial Hospital of Sun Yat-sen University.ParticipantsWe included a population sample of 997 subjects aged 40 years or older.Primary and secondary outcome measuresThe LAP was calculated by gender-specific equations using waist circumference (WC) and triglyceride (TG). LOH was defined by the presence of androgen deficiency symptoms and low serum total testosterone levels.ResultsThe prevalence of LOH was 9.4% in this population and gradually increased according to increasing LAP quartiles. Compared with subjects without LOH, ageing men with LOH had higher body mass index, WC, systolic blood pressure, percentage of subjects currently smoking, TG and follicle stimulating hormone and lower low-density lipoprotein cholesterol and sex hormone binding globulin. In multivariate logistic regression analysis, the adjusted ORs of LOH for increasing LAP quartiles 1–4 were 1.00 (reference), 1.10 (95% CI 0.45–2.69), 2.15 (95% CI 0.93–4.94) and 3.83 (95% CI 1.73–8.45), respectively.ConclusionBody lipid accumulation evaluated by the LAP is independently associated with the prevalence of LOH in middle-aged and elderly Chinese men.

show abstract

“…These results don’t support a protective role of TRT towards patients with a history of PCa, but encourage broaden research in this way. 91 , 94 …”

Section: Effects Of the Treatment In Patients With Prostatic Diseasesmentioning

confidence: 99%

Systemic effects of the hormonal treatment of male hypogonadism with preliminary indications for the management of COVID-19 patients

Cannarella

Calogero

Condorelli

et al. 2020

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Male hypogonadism, defined as an inadequate production of testosterone (T), is associated with a greater morbidity and mortality. Epidemiological studies identified T deficiency as a risk factor for cardiovascular disease. Also, low serum T levels impact on glucose homeostasis through a worse glucose uptake, utilization, and disposal, and the general negative impact on metabolism. The aim of this review is to provide a comprehensive and updated overview of the effects of T replacement therapy on metabolic and cardiovascular systems and prostate tissue in patients with hypogonadism, including molecular mechanisms through which T exerts its actions. Furthermore, recent findings on novel coronavirus disease (COVID-19) epidemiology have shown a greater mortality in male compared with female patients and a role of T in promoting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection of the host cells has been demonstrated. Hence, the secondary aim of this review is to provide preliminary indications on the management in patients with COVID-19.

show abstract

Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology

Cited by 28 publications

References 64 publications

Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study

Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study

Lipid accumulation product and late-onset hypogonadism in middle-aged and elderly men: results from a cross-sectional study in China

Systemic effects of the hormonal treatment of male hypogonadism with preliminary indications for the management of COVID-19 patients

Contact Info

Product

Resources

About